Tranzyme (TZYM) Drops After Disappointing ULISES 007 Trial Results
Tranzyme Inc. (NASDAQ:TZYM), a clinical-stage bio-pharmaceutical company, said the preliminary analysis of its ULISES 007 pivotal trial evaluating ulimorelin indicated study failed to meet its primary and secondary efficacy endpoints, sending its shares 70.59% lower in premarket trading. [More...]
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here